Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020046 · ClinicalTrials.gov registry record · Phase 2
Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
A Phase 2 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00020046 is a Phase 2 study that has completed, run by National Institutes of Health Clinical Center (CC).
The verdict
NCT00020046, a Phase 2 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. PURPOSE: Randomized phase II trial to compare the effectiveness of docetaxel with or without thalidomide in treating patients who have metastatic prostate cancer.
Interventions
- DRUG docetaxel
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-12 |
| Est. Completion | 2003-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00020046
The ClinicalTrials.gov registry entry for NCT00020046 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00020046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00020046 about?
NCT00020046 is a clinical study titled "Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. PURPOSE: Randomized phase II trial to compare the effectiveness of docetaxel with or withou...
What is the current status of trial NCT00020046?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-12. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00020046?
The interventions under investigation include: docetaxel (DRUG), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00020046?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.